High-dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda
Key facts
- Who runs it
- Virginia Commonwealth University
- Where
- Rwanda1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 3
- Started
- Oct 2022
- Ended
- Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ascorbic Acid 500Mg/Ml Inj
- Dextrose in Water
- Record updated
- 18 October 2022
- Why it stopped
- Recent studies suggest an increase in mortality due to high-does Vitamin C
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adult patients between the ages of 18 and 80 who provide informed consent (or consent obtained by family member if patient is incapacitated) AND
- Patients with a strong suspicion or confirmation of infection AND
- Presence of organ dysfunction brought on by sepsis. This defined by an increase of two or more points in the qSOFA score
Who cannot take part
- Known allergic reaction to ascorbic acid
- History of renal stones
- History of end-stage renal disease (ESRD) requiring dialysis
- History of hemochromatosis
- History of glucose-6-phosphatase dehydrogenase (G6PD) deficiency
- Pregnant patients or those who may be pregnant
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This feasibility study serves to determine if it is possible to perform a powered randomized control trial of high-dose intravenous vitamin C (ascorbic acid) as an adjunctive medication in the management of sepsis and septic shock in Rwanda. Further data will be collected including Sequential Organ Failure Assessment (SOFA) score, Universal Vital Assessment (UVA) score, duration of vasopressors, mortality and other key indicators to possibly determine the impact of vitamin C on organ failure and clinical course. A total of 24 patients with a diagnosis of sepsis or septic shock will be recruited after obtaining informed consent at the University Teaching Hospital of Kigali (CHUK) and will be randomized in a 1:1 fashion to receive drug or placebo. Both treatment arms will receive standard treatment (intravenous fluids, antibiotics, vasopressors as needed, etc.) in addition to study drug or placebo.
Read full original descriptionShow less
During the course of the study, any difficulties encountered will be recorded and will inform process improvements for a full randomized control, if it is indeed considered possible to perform the definitive trial.
The 2 groups in the trial
- Treatment armTreatment being tested
The study drug is ascorbic acid is 200mg/kg/day divided over 4 doses per day and delivered in 50 ml of 5% dextrose in water intravenously over a total duration of 96 hours.
Treatment: Ascorbic Acid 500Mg/Ml Inj
- Placebo armPlacebo, for comparison
The placebo is 50ml of 5% dextrose in water and will be administered 4 doses per day over a total duration of 96 hours
Treatment: Dextrose in Water
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- High-dose Intravenous Vitamin C as an Adjunctive Treatment for Sepsis in Rwanda: a Feasibility Trial
- Record updated
- 18 October 2022